Assistant Clinical Professor, Endocrinology, University of Texas Medical School at Houston
Endocrinology
Dr. Mimi I. Hu, MD
|
|
Give Review
Mimi I. Hu works in the field of Endocrinology. She went to Baylor College of Medicine. She received awards:"Top Doctors:SE Texas" and "Super Doctor". Mimi is also published. She has 32 publications published. The lastest publication: "Incidence of Atypical Femur Fractures in Cancer Patients: The MD Anderson Cancer Center Experience.' Dr. Mimi I. Hu accepts Medicare payments and is listed with Medicare.gov.
Publications
- Preexisting adrenal masses in patients with adrenocortical carcinoma: clinical and radiological factors contributing to delayed diagnosis.
- Incidence of Atypical Femur Fractures in Cancer Patients: The MD Anderson Cancer Center Experience.
- Thyroid Gland Malignancies.
- Denosumab: a new agent in the management of Hypercalcemia of malignancy.
- Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary Thyroid cancer: M.D. Anderson Cancer Center off label experience.
- Medullary Thyroid Cancer in the Era of Tyrosine Kinase Inhibitors: To Treat or Not to Treat-And with Which Drug-Those Are the Questions.
- Vitamin D Deficiency in Mycosis Fungoides and Sézary Syndrome Patients Is Similar to Other Cancer Patients.
- Role of salvage targeted therapy in differentiated Thyroid cancer patients who failed first-line sorafenib.
- Update on Medullary Thyroid Cancer.
- Denosumab for Treatment of Hypercalcemia of Malignancy.
- Efficacy and Tolerability of Different Starting Doses of Sorafenib in Patients With Differentiated Thyroid Cancer.
- Prevalence by Age and Predictors of Medullary Thyroid Cancer in Patients with Lower Risk Germline RET Proto-Oncogene Mutations.
- Aerodigestive Fistula Formation as a Rare Side Effect of Antiangiogenic Tyrosine Kinase Inhibitor Therapy for Thyroid Cancer.
- Denosumab for Patients With Persistent or Relapsed Hypercalcemia of Malignancy Despite Recent Bisphosphonate Treatment.
- The Characterization of Pheochromocytoma and Its Impact on Overall Survival in Multiple Endocrine Neoplasia Type 2.
- Two birds with one stone: octreotide treatment for acromegaly and breast Cancer.
- The Noninvestigational Use of Tyrosine Kinase Inhibitors in Thyroid Cancer: Establishing a Standard for Patient Safety and Monitoring.
- Preoperative serum osteocalcin may predict postoperative elevated paraThyroid hormone in patients with primary hyperparaThyroidism.
- Medullary Thyroid Carcinoma: Who's on First?
- Predictable Criteria for Selective, Rather Than Routine, Calcium Supplementation Following Thyroidectomy.
- Updates in the management of medullary Thyroid cancer.
- Cushing Syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center Experience.
- Medical management of postsurgical hypoparaThyroidism.
- Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary Thyroid carcinoma compared with a RET M918T mu...
- Challenges associated with tyrosine kinase inhibitor therapy for metastatic Thyroid cancer.
- Cancer therapies and bone health.
- Skeletal sequelae of Cancer and Cancer treatment.
- Management of medullary Thyroid carcinoma.
- Recent advances in Thyroid cancer. In brief.
- Recent advances in Thyroid cancer.
- Bone loss in patients with breast or prostate Cancer.
Schools
University of Texas At Houston Medical School At Houston
Baylor College Of Med
Conditions Treated
- Abnormal Thyroid
- Calcium Metabolism Disorders
- Cushing's Syndrome
- Diabetes Insipidus
- View All
Doctors Specialties
- Endocrinology
Accepted Insurances
Awards
- Top Doctors:SE Texas
- Super Doctor
Education
-
Baylor College of Medicine -
University of Texas Medical School
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1497962252 | |
| NPPES Provider LastName | HU | |
| NPPES Provider FirstName | MIMI | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Endocrinology | |
| Total Claim Count | 443.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 12.0 | |
| Percent Opioid Claims | 2.71 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1497962252 |
| Last Name Of The Provider | HU |
| First Name Of The Provider | MIMI |
| View All |
Similar Doctors
|
Dr. Vivian O. Rodriguez, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Jyothi M. Juarez, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Damaris Vega, MD
This Doctor is OpenDoctor Recommended.
|